Skip to content

Acetyl-L-carnitine and global cognition: grade C

Limited evidence. Direction: No effect.

Evidence maturity: Established

Why this grade

Rubric condition met: Results only in clinical/older populations (mild cognitive impairment, Alzheimer's disease) being extrapolated to healthy adults

All controlled evidence is in people with mild cognitive impairment or Alzheimer's disease. A 2003 meta-analysis found a small advantage over placebo (ES 0.201), but a 2003 Cochrane review of 11 trials found no evidence of benefit on objective cognitive measures, and two 1-year trials (431 and 229 patients) found no slowing of decline. The only healthy-adult data found is an uncontrolled pilot of 17 young adults. Direction is none because the larger trials were null. N is not available without adequate RCTs in the relevant population, so the grade is C with direction none, read as limited and mixed.

How sure are we?

Evidence maturity: Established A meta-analysis of more than 5 RCTs from more than one group in people with MCI or Alzheimer's disease (clinical population). The trials predate routine registration, so preregistration is unconfirmed; the C comes from the population cap.

Tested as: Acetyl-L-carnitine

Who paid for the studies
Not stated (treated as not independent)
Risk of bias
Some concerns. One 1-year trial lists two Sigma-Tau authors; others do not state funding.
Trial registry check
Not checked yet
Outcome measured
A test score, rating scale or performance measure
Who was studied
Clinical populations only
Doses used in studies
1.5-3.0 g a day
Rules applied
Population cap (logged, no further change): Clinical populations only
  • Could rise: Would move to C benefit for healthy adults only with a preregistered RCT of at least 100 healthy adults positive on a prespecified cognitive primary outcome.
  • Could fall: Would move to N (clinical population) if a new meta-analysis restricted to placebo-controlled trials were null on objective cognition.

Science is provisional. This grade reflects the evidence we found as of . Next review: .

Maturity sits beside each grade. The grade says what the evidence shows; maturity says how much of it there is and how well it is confirmed.

Established
many trials from several independent teams, including at least one registered in advance
Emerging
two or more trials, or one large registered trial, not yet independently confirmed
Early signal
one trial, small pilots, or results only on secondary outcomes
Mechanistic only
lab, animal or biomarker data, or uncontrolled reports; no controlled human results
Traditional use only
a traditional-use monograph and nothing else

How we grade evidence

Studies this grade rests on

EffectMixedNo effectSize shows participants (n)1990200020102020Meta-analysisSystematic reviewRCTNarrative reviewThal 1996, 1996: RCT, n = 431, result not recordedThal 2000, 2000: RCT, n = 229, result not recordedLino 1992, 1992: RCT, n = 17, result not recordedPennisi 2020, 2020: narrative review, n not recorded, result not recordedHudson 2003, 2003: systematic review, n not recorded, result not recordedMontgomery 2003, 2003: meta-analysis, n not recorded, result not recorded
each study this grade rests on, by publication year and design. Solid: effect versus the comparator; half-filled: mixed; hollow: no effect; dashed: result not recorded yet. Larger marks had more participants.
Show the numbers
StudyYearDesignParticipantsResult
Lino 19921992RCT17result not recorded
Thal 19961996RCT431result not recorded
Thal 20002000RCT229result not recorded
Hudson 20032003systematic reviewnot recordedresult not recorded
Montgomery 20032003meta-analysisnot recordedresult not recorded
Pennisi 20202020narrative reviewnot recordedresult not recorded

[Psycho-functional changes in attention and learning under the action of L-acetylcarnitine in 17 young subjects. A pilot study of its use in mental deterioration].

Lino A, Boccia MM, Rusconi AC. [Psycho-functional changes in attention and learning under the action of L-acetylcarnitine in 17 young subjects. A pilot study of its use in mental deterioration] Clin Ter, 1992. PMID 1638856

Result not recorded
Design
Uncontrolled pilot study, with an untreated control group for one test (not randomized, not placebo-controlled)
Sample
n = 17
Population
Healthy young adults aged 22-27
Funding
not stated

Acetyl-L-Carnitine in Dementia and Other Cognitive Disorders: A Critical Update.

Pennisi M, Lanza G, Cantone M. Acetyl-L-Carnitine in Dementia and Other Cognitive Disorders: A Critical Update Nutrients, 2020. PMID 32408706

Result not recorded
Design
Narrative review
Population
People with dementia and other cognitive disorders (clinical populations)
Funding
not stated

A 1-year controlled trial of acetyl-l-carnitine in early-onset AD.

Thal LJ, Calvani M, Amato A. A 1-year controlled trial of acetyl-l-carnitine in early-onset AD Neurology, 2000. PMID 10994000

Result not recorded
Design
1-year multicenter double-blind randomized placebo-controlled trial
Sample
n = 229
Population
Adults aged 45-65 with early-onset probable Alzheimer's disease (clinical population)
Funding
not stated; manufacturer-affiliated co-authors (see industry_note)

A 1-year multicenter placebo-controlled study of acetyl-L-carnitine in patients with Alzheimer's disease.

Thal LJ, Carta A, Clarke WR. A 1-year multicenter placebo-controlled study of acetyl-L-carnitine in patients with Alzheimer's disease Neurology, 1996. PMID 8797468

Result not recorded
Design
1-year multicenter double-blind randomized placebo-controlled trial
Sample
n = 431
Population
Adults aged 50 or older with mild to moderate probable Alzheimer's disease (clinical population)
Funding
not stated

Acetyl-L-carnitine for dementia.

Hudson S, Tabet N. Acetyl-L-carnitine for dementia Cochrane Database Syst Rev, 2003. PMID 12804452

Result not recorded
Design
Cochrane systematic review of 11 double-blind randomized placebo-controlled trials
Population
People with Alzheimer's disease (clinical population)
Funding
not stated

Meta-analysis of double blind randomized controlled clinical trials of acetyl-L-carnitine versus placebo in the treatment of mild cognitive impairment and mild Alzheimer's disease.

Montgomery SA, Thal LJ, Amrein R. Meta-analysis of double blind randomized controlled clinical trials of acetyl-L-carnitine versus placebo in the treatment of mild cognitive impairment and mild Alzheimer's disease Int Clin Psychopharmacol, 2003. PMID 12598816

Result not recorded
Design
Meta-analysis of double-blind, placebo-controlled parallel-group trials of at least 3 months
Population
Adults with mild cognitive impairment or mild Alzheimer's disease (clinical population)
Funding
not stated

Search and history

Search (): (acetylcarnitine[ti] OR acetyl-L-carnitine[ti] OR "acetyl L carnitine"[ti]) AND (cognitive[tiab] OR memory[tiab] OR cognition[tiab] OR dementia[tiab] OR cognitive impairment[tiab]) AND (meta-analysis[pt] OR systematic review[pt])

  • Graded C (awaiting approval)
  • C to C (awaiting approval) (maturity: established): Maturity, bias summary and re-check date added
  • C to C (approved) (maturity: established): Editor sign-off November 16, 2026: grade matches the editor-approved final page